Genitourinary Cancer

PV QA 1 - Poster Viewing Q&A 1

SU_20_2205 - Radiation Therapy as Definitive Local Treatment in Patients with Small Cell Carcinoma of the Bladder: Does total dose matter? A National Cancer Database Analysis.

Sunday, October 21
1:15 PM - 2:45 PM
Location: Innovation Hub, Exhibit Hall 3

Radiation Therapy as Definitive Local Treatment in Patients with Small Cell Carcinoma of the Bladder: Does total dose matter? A National Cancer Database Analysis.
E. A. Germino1, B. W. Fischer-Valuck2, S. Rudra2, J. M. Michalski3, and H. A. Gay4; 1Washington University in St. Louis, St. Louis, MO, 2Washington University School of Medicine, Department of Radiation Oncology, St. Louis, MO, 3Washington University School of Medicine, St. Louis, MO, 4Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO

Purpose/Objective(s): To determine whether total radiation dose correlates with survival outcomes for patients with small cell carcinoma of the bladder (SCCB).

Materials/Methods: We queried the National Cancer Database (NCDB) for patients with limited stage SCCB undergoing multimodality treatment and retrospectively analyzed survival outcomes according to total radiation dose received.

Results: Our cohort included 192 patients that received either chemoradiation (183) or radical cystectomy with chemoradiation (9), with a median follow-up of 23.9 months. Patients aged 41-75 receiving a total radiation dose of 54 Gy or greater had a statistically significant improvement in overall survival compared to those receiving less than 54 Gy, with a median overall survival of 68.1 months (95% confidence interval [CI] 43.8 - 92.3 months) compared to 25.9 months (95% CI 18.9 - 32.9 months) (p < 0.05). There was no statistically significant difference in outcomes for patients receiving between 54 and 60 Gy compared to those receiving 60 Gy or higher. There was also no difference in outcomes based on total radiation dose for patients over 75 years old, even when limiting analysis to patients with a Charlson-Deyo comorbidity index score of 0.

Conclusion: For patients aged 75 or younger with limited stage SCCB, total radiation dose of 54 Gy or greater may be associated with better overall survival.

Author Disclosure: E.A. Germino: None. B.W. Fischer-Valuck: None. S. Rudra: None. J.M. Michalski: Independent Contractor; Sheila Michalski and Associates. Research Grant; NCI. https://medicine.wustl.edu/news/effort-improve-radiation-therapy-veterans-receives-nearly-4-million/; Veteran's Administration. Consultant; Veteran's Administration. Stock; ViewRay Inc. Chair Radiation Oncology Committee; NRG Oncology. Radiation Oncology Practice Assessment; Veterans Affairs. Co-chair GU Steering Committee; NCI.

Send Email for Elizabeth Germino


Assets

SU_20_2205 - Radiation Therapy as Definitive Local Treatment in Patients with Small Cell Carcinoma of the Bladder: Does total dose matter? A National Cancer Database Analysis.



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Radiation Therapy as Definitive Local Treatment in Patients with Small Cell Carcinoma of the Bladder: Does total dose matter? A National Cancer Database Analysis.